Viewing nowCombinationYumero Tablet 20/10mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202003954 · Approved 2020.05.28
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerotic progression and prevention of cardiovascular disease
This medication is used for patients who need to simultaneously treat hypertension and hyperlipidemia. Olmesartan Medoxomil effectively improves essential hypertension, while Rosuvastatin helps treat hypercholesterolemia and various dyslipidemias. Additionally, Rosuvastatin is used to slow the progression of atherosclerosis and reduce the risk of cardiovascular diseases. In particular, it reduces the risk of stroke, myocardial infarction, and artery revascularization in men over 50 years old and women over 60 years old with multiple cardiovascular risk factors. By combining these two medications, blood pressure and cholesterol levels are controlled and cardiovascular health is improved.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Safety and efficacy in children under 18 years of age have not been established.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to this drug or any of its components, pregnant or potentially pregnant women, and nursing mothers should not take this medication. Patients with severely impaired kidney function or undergoing kidney dialysis, severe liver disease, biliary obstruction, or muscle disorders should not use this medication. Patients with low blood pressure or insufficient body salt may experience hypotension at the beginning of treatment with this medication, so careful monitoring is required. Patients with poor kidney function or those who have received a kidney transplant should frequently check kidney function and electrolyte levels through blood tests. This medication can increase blood potassium levels; therefore, patients at risk of hyperkalemia should regularly monitor their potassium levels. Patients with weak liver function or a history of liver disease should have liver function tests regularly and should discontinue use if symptoms of liver damage appear. This medication can cause muscle pain, muscle weakness, and rarely serious muscle damage (rhabdomyolysis); therefore, if symptoms of muscle pain or weakness occur, the doctor must be notified immediately. Dizziness may occur during the use of this medication, so caution is advised when operating dangerous machinery or driving. This medication may interact with other drugs, so if there are any other medications being taken, it is essential to inform the doctor or pharmacist, especially with potassium-sparing diuretics, lithium, nonsteroidal anti-inflammatory drugs, and certain antibiotics or antifungals. This medication should not be used during pregnancy or breastfeeding, and women of childbearing age should use appropriate contraceptive methods. The safety and efficacy in children under 18 years of age have not been established. Elderly patients may experience increased concentrations of this medication in their body, so dose adjustment may be necessary. In case of overdose, symptoms such as hypotension or cardiac arrhythmias may occur, so medical attention should be sought immediately, and since there is no specific antidote, treatment will depend on the symptoms. This medication should be kept out of the reach of children and should not be transferred to other containers.
Elevated ALT, elevated AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, decreased sensation, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome-like intestinal disorder, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, positional dizziness included, palpitations, hypertension, low back pain, pruritus, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, pancreatitis, rash and urticaria, myopathy including myositis, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders including insomnia and nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it must be stored in a sealed container. It is best to keep the storage temperature between 1 and 30 degrees Celsius.
White or yellowish round film-coated tablets
30 tablets/box [30 tablets (10 tablets/Alu-Alu) × 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.